Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2010

Roche Pays About $8.7M to Partner with Galapagos for COPD Target and Drug Discovery

  • Roche is paying Galapagos €6 million (about $8.7 million) up front as part of a multiyear alliance to develop new treatments for chronic obstructive pulmonary disease (COPD). Galapagos could potentially receive in excess of another €400 million (roughly $580.32 million) in discovery, development, regulatory, and sales milestones.

    Under the terms of the partnership, Galapagos will use its discovery platform to identify novel COPD targets. The company will also be responsible for the discovery and development of new small molecule candidates against the new targets.

    Roche has an exclusive option to license each small molecule program either after clinical-candidate selection or after the completion of Phase I trials. On exercising an option the company will take over all further development and commercialization. Roche may also license the COPD targets for the discovery and development of novel antibodies.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »